Holen Sie sich die Stockscreener-App
106.92
0.46%
-0.49
Handel nachbörslich:
106.85
-0.07
-0.07%
Insmed Inc Aktie (INSM) Neueste Nachrichten
Insmed chair and CEO William Lewis sells over $1.1m in company stock - Investing.com Australia
Form 4 Insmed Inc For: 24 July By Investing.com - Investing.com Canada
Insmed Incorporated Revenue Breakdown – LSE:0JAV - TradingView
Insmed Inc. CEO William Lewis Executes Key Stock Option Acquisitions and Share Sales - Kalkine Media
Insmed (INSM) CEO trades 10,700 shares after option exercise - Stock Titan
Concerns Over the Pace of its Brinsupri’s Launch Hurt Insmed (INSM) - Yahoo Finance
Insmed and Ty Pennington team up - WFLA
Form 144 INSMED INC For: 24 July - Investing.com UK
Form 144 INSMED INC For: 24 July By Investing.com - Investing.com South Africa
INSMED INC (INSM.MX) Q1 FY2026 earnings call transcript - Yahoo Finance
Insmed (INSM) insider William Lewis plans 10,700-share stock sale - Stock Titan
William Haggerty Joins Insmed Incorporated as Senior Director of People Operations - hrtoday.in
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - Stocktwits
Insmed's second-quarter business update will be webcast Aug. 6 - Stock Titan
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits
Guggenheim Reaffirms Their Buy Rating on Insmed (INSM) - The Globe and Mail
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
JPMorgan Chase & Co. (INSM) reports 10.37M Insmed shares, a 4.7% stake - Stock Titan
Guggenheim Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $207 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
INSM Initiated Coverage by BMO Capital -- Price Target Announced at $192 - GuruFocus
BMO Capital Initiates Insmed at Outperform With $192 Price Target - marketscreener.com
Is Insmed (INSM) Priced Too Richly For Its Phase 3 Progress? - Yahoo Finance
Insmed (INSM) Following TPIP 12 Month Data, Does The Valuation Still Stack Up - Yahoo Finance
BMO initiates Insmed stock with outperform rating on respiratory franchise potential - Investing.com Nigeria
Insmed Announces Positive 12-Month Data from OLE Study of Inhalation Solution for Pulmonary Arterial Hypertension - dicardiology.com
Positive 12‑Month TPIP PAH Data Could Be A Game Changer For Insmed (INSM) - Yahoo Finance
Buy Insmed for a double, this analyst says - Cantech Letter
Investors’ Concerns Hurt Insmed Incorporated (INSM) Despite Better-Than-Expected Results - Yahoo Finance
Insmed stock price target maintained at $220 by H.C. Wainwright - Investing.com Canada
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Insmed (INSM) Reports 12 Month TPIP Data That Sets Up Phase 3 - webull.com
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $161 to $237 - Moomoo
Open-label extension drives home benefits of Insmed’s PAH therapy - BioWorld News
Insmed stock price target maintained at $200 by Stifel on trial data - Investing.com Canada
Insmed Sees Sustained Gains With Inhaled Drug for Stressed Heart Functioning - Benzinga
INSM: TPIP sustained robust efficacy and safety at 12 months, with 65% reaching refined low-risk status - TradingView
Insmed (INSM) Reports Promising 12-Month Results for TPIP in PAH Patients - GuruFocus
Insmed's TPIP Shows Durable PAH Benefits in 12-Month Study - Yahoo Finance
INSM: TPIP sustained best-in-class efficacy and safety at 12 months, with 65% reaching low-risk status - TradingView
Insmed Says Treprostinil Shows Sustained Benefit to Pulmonary Arterial Hypertension Patients - Moomoo
Insmed reports 12-month data for PAH treatment candidate By Investing.com - Investing.com Canada
Insmed reports 12-month data for PAH treatment candidate - Investing.com
Insmed reports positive 12-month OLE results for TPIP showing sustained 6MWD, ~60% NT-proBNP drop - TradingView
Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension - PR Newswire
About 65% of TPIP Patients Reach Refined Low Risk Status - Stock Titan
INSM Stock Dips In Extended Trading After Experimental Skin Disease Drug Fails In Study - Stocktwits
INSM Maintained by Wells Fargo -- Price Target Raised to $161 - GuruFocus
Enterprise value to EBIT forward of Insmed Incorporated – BMV:INSM - TradingView
MSN Money - MSN
0.84%
0.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):